Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Latest from Vanderbilt-Ingram Cancer Center

How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

December 06, 2024

Podcast

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

November 22, 2024

Article

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

October 18, 2024

Article

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

The New Era of Clinical Trial Design

October 18, 2024

Article

Jill Gilbert, MD, highlights a recent landmark decision by the FDA concerning trial design moving forward for cancer drugs.

Dr Eng on Unmet Needs Within the mCRC Treatment Paradigm

September 30, 2024

Video

Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15, 2024

Article

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

July 23, 2024

Video

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

July 21, 2024

Article

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

Dr Philip on the Development of T-Cell Dysfunction in Liver Cancer and Melanoma Cell Models

July 09, 2024

Video

Mary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.

Dr Lovly on the Investigation of BDTX-1535 in NSCLC

May 31, 2024

Video

Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Dr Baljevic on the PERSEUS Trial in Untreated Multiple Myeloma

May 28, 2024

Video

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Data for Quadruplet Therapies Could Alter Frontline SOC for Transplant-Ineligible Multiple Myeloma

May 28, 2024

Article

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

May 25, 2024

Article

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies

May 24, 2024

Article

Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.

Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALL

May 23, 2024

Video

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

May 22, 2024

Article

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.

Dr Neelapu on Addressing CAR T-Cell Resistance in Lymphoma

May 22, 2024

Video

Sattva S. Neelapu, MD, discusses mechanisms of resistance to CAR T-cell therapies in lymphoma and how these areas of need may be addressed.

Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis

May 21, 2024

Article

Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.

Dr Beckermann on Targeting TREM2 in the Treatment of ccRCC

May 07, 2024

Video

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune Disorders

May 02, 2024

Video

Olalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.